ストックスクリーナーアプリを入手
5.11
4.66%
-0.25
アフターアワーズ：
5.11
前日終値:
$5.36
開ける：
$5.3
24時間の取引高:
223.69K
Relative Volume:
0.67
時価総額：
$279.91M
収益：
-
当期純損益:
$-72.89M
株価収益率:
-2.1116
EPS:
-2.42
ネットキャッシュフロー:
$-68.47M
1週間 パフォーマンス:
+3.02%
1か月 パフォーマンス:
+9.77%
6か月 パフォーマンス:
-55.60%
1年 パフォーマンス:
-46.49%
1日の値動き範囲:
$5.10
$5.36
1週間の範囲:
$5.01
$5.47
52週間の値動き範囲:
$3.555
$12.92
Astria Therapeutics Inc Stock (ATXS) Company Profile
ATXS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ATXS
Astria Therapeutics Inc
|
5.11 | 279.91M | 0 | -72.89M | -68.47M | -2.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Astria Therapeutics Inc Stock (ATXS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-29 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-01-31 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-07-29 | 開始されました | TD Cowen | Buy |
| 2023-03-28 | 開始されました | Evercore ISI | Outperform |
Astria Therapeutics Inc (ATXS) 最新ニュース
Astria Therapeutics Inc expected to post a loss of 48 cents a shareEarnings Preview - TradingView
Invesco Ltd. Has $161,000 Holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ATXS Stock News - GuruFocus
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Wall Street analysts’ outlook for Astria Therapeutics Inc (ATXS) - Sete News
Financial Metrics Check: Astria Therapeutics Inc (ATXS)’s Ratios for Trailing Twelve Months - DWinneX
Brokers Set Expectations for ATXS FY2025 Earnings - Defense World
Breaking down ATXS’s current quarter earnings estimates - uspostnews.com
Astria Therapeutics Announces Publication of Navenibart Phase 1a - GuruFocus
Astria Therapeutics reports progress in HAE drug trial By Investing.com - Investing.com India
Astria Therapeutics Announces Publication of Navenibart Phase 1a Healthy Subject Results in the Annals of Allergy, Asthma & Immunology - Business Wire
Astria Therapeutics, Inc. (NASDAQ:ATXS) Holdings Increased by Legal & General Group Plc - Defense World
Astria Therapeutics (ATXS) to Release Quarterly Earnings on Thursday - Defense World
Astria Therapeutics, Inc. (NASDAQ:ATXS) Position Increased by JPMorgan Chase & Co. - Defense World
Astria Therapeutics to Present at Upcoming Citizens Life Sciences Conference | ATXS Stock News - GuruFocus
Cantor Fitzgerald Upgrades Astria Therapeutics (NASDAQ:ATXS) to “Strong-Buy” - Defense World
Astria Therapeutics to Present at Upcoming Citizens Life Sciences Conference - Business Wire
Astria Therapeutics (ATXS) Receives Overweight Rating with Promi - GuruFocus
Cantor Fitzgerald Initiates Coverage of Astria Therapeutics (ATXS) with Overweight Recommendation - Nasdaq
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives $26.60 Consensus Price Target from Analysts - Defense World
Ratios Revealed: Decoding Astria Therapeutics Inc (ATXS)’s Financial Health - DWinneX
Astria Therapeutics Inc (ATXS) stock analysis: A simple moving average approach - uspostnews.com
Geode Capital Management LLC Sells 2,770 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
ATXS’s Stock Dilemma: Astria Therapeutics Inc’s Market Performance and Outlook - investchronicle.com
Top Premarket Decliners - marketscreener.com
Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Purchased by Vanguard Group Inc. - Defense World
Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Bought by American Century Companies Inc. - Defense World
KLP Kapitalforvaltning AS Takes Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Raymond James Financial Inc. Takes $707,000 Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Long Term Trading Analysis for (ATXS) - news.stocktradersdaily.com
Teacher Retirement System of Texas Makes New Investment in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Astria Therapeutics Grants $235K Worth of Stock Options to Strategic New Hires - Stock Titan
Analysts Set Astria Therapeutics, Inc. (NASDAQ:ATXS) PT at $26.60 - Defense World
Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Purchased by Swiss National Bank - Defense World
Charles Schwab Investment Management Inc. Increases Stake in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
(ATXS) Investment Report - news.stocktradersdaily.com
Q1 EPS Estimates for Astria Therapeutics Cut by Wedbush - The AM Reporter
What is HC Wainwright’s Forecast for ATXS Q1 Earnings? - Defense World
Lifesci Capital Has Pessimistic View of ATXS FY2025 Earnings - Defense World
Q1 EPS Forecast for Astria Therapeutics Decreased by Analyst - Defense World
Astria Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
(ATXS) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Astria Therapeutics price target raised to $28 from $27 at Wedbush - TipRanks
Wedbush Adjusts Price Target on Astria Therapeutics to $28 From $27, Keeps Outperform Rating - Marketscreener.com
Astria Therapeutics (NASDAQ:ATXS) Given Buy Rating at HC Wainwright - Defense World
Astria Therapeutics Advances Clinical Trials and Financials - TipRanks
Astria Therapeutics: Promising Developments and Strategic Advancements Justify Buy Rating - TipRanks
Astria Therapeutics, Inc. SEC 10-K Report - TradingView
Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update - BioSpace
Astria Therapeutics: Promising Pipeline and Strong Financials Drive Buy Rating - TipRanks
Preclinical data reported for Astria’s anti-OX40 monoclonal antibody - BioWorld Online
Astria Therapeutics Inc (ATXS) 財務データ
収益
当期純利益
現金流量
EPS
0.39%
3.66%
大文字化:
|
ボリューム (24 時間):